Drug Trial Radar · NCT06160609
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
9
Actual
Start
Oct 7, 2019
Primary completion
Jan 9, 2023
Study completion Jan 9, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination treatment to explore in the cohort expansion phase. This study is the sub study of the Master protocol (NCT04126200).
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
Belantamab MafodotinDrug
Belantamab Mafodotin will be administered.
GSK3174998Drug
GSK3174998 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DE Phase: Number of Participants With Dose Limiting Toxicities (DLT)Time frame: Up to 21 days
- DE Phase: Number of Participants With Adverse Events (AEs)Time frame: Up to 170 weeks
- DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to BaselineTime frame: Baseline (Day 1) and up to 170 weeks
- DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to BaselineTime frame: Baseline (Day 1) and up to 170 weeks
- Cohort Expansion (CE) Phase: Overall Response Rate (ORR)Time frame: Up to 170 weeks
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Fitzroy, Victoria, Australia
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.